,address1,address2,city,state,zip,country,phone,fax,website,industry,sector,longBusinessSummary,fullTimeEmployees,companyOfficers,compensationAsOfEpochDate,maxAge,priceHint,previousClose,open,dayLow,dayHigh,regularMarketPreviousClose,regularMarketOpen,regularMarketDayLow,regularMarketDayHigh,payoutRatio,beta,forwardPE,volume,regularMarketVolume,averageVolume,averageVolume10days,averageDailyVolume10Day,bid,ask,bidSize,askSize,marketCap,fiftyTwoWeekLow,fiftyTwoWeekHigh,priceToSalesTrailing12Months,fiftyDayAverage,twoHundredDayAverage,trailingAnnualDividendRate,trailingAnnualDividendYield,currency,enterpriseValue,profitMargins,floatShares,sharesOutstanding,sharesShort,sharesShortPriorMonth,sharesShortPreviousMonthDate,dateShortInterest,sharesPercentSharesOut,heldPercentInsiders,heldPercentInstitutions,shortRatio,shortPercentOfFloat,bookValue,priceToBook,lastFiscalYearEnd,nextFiscalYearEnd,mostRecentQuarter,netIncomeToCommon,trailingEps,forwardEps,lastSplitFactor,lastSplitDate,enterpriseToRevenue,enterpriseToEbitda,exchange,quoteType,symbol,underlyingSymbol,shortName,longName,firstTradeDateEpochUtc,timeZoneFullName,timeZoneShortName,gmtOffSetMilliseconds,currentPrice,targetHighPrice,targetLowPrice,targetMeanPrice,targetMedianPrice,recommendationMean,recommendationKey,numberOfAnalystOpinions,totalCash,totalCashPerShare,ebitda,totalDebt,quickRatio,currentRatio,totalRevenue,debtToEquity,revenuePerShare,returnOnAssets,returnOnEquity,grossProfits,freeCashflow,operatingCashflow,revenueGrowth,grossMargins,ebitdaMargins,operatingMargins,financialCurrency,trailingPegRatio
0,Cedar Brook Corporate Center,4-B Cedar Brook Drive,Cranbury,NJ,08512,United States,609 495 2200,609 495 2202,https://palatin.com,Biotechnology,Healthcare,"Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL3994, a peptide mimetic molecule with amino acid mimetic structure and amino acids properties; and L8177, an oral peptide formulation for treatment of ulcerative colitis, which entered Phase 2 clinical trials. The company was founded in 1986 and is based in Cranbury, New Jersey.",33,"{'maxAge': 1, 'name': 'Dr. Carl  Spana Ph.D.', 'age': 60, 'title': 'Co-Founder, Pres, CEO & Director', 'yearBorn': 1962, 'fiscalYear': 2022, 'totalPay': 943250, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,2.06,2.05,1.8,2.1094,2.06,2.05,1.8,2.1094,0.0,0.951244,-1.011236,242397,242397,83062,88300,88300,1.75,1.95,900,4000,20742300,1.8,8.6,5.3701982,2.2054,2.71785,0.0,0.0,USD,1909782,0.0,10521404,11523500,374540,401086,1690761600,1693440000,0.0325,0.06579,0.19712,3.25,0.033,0.86,2.093023,1656547200,1688083200,1680220800,-29595042,-2.55,-1.78,1:10,1285545600,0.494,-0.054,ASE,EQUITY,PTN,PTN,"Palatin Technologies, Inc.","Palatin Technologies, Inc.",876922200,America/New_York,EDT,-14400000,1.8,70.0,9.0,43.0,50.0,1.3,strong_buy,3,19632330,1.704,-35519496,799798,1.8,2.045,3862483,8.338,0.373,-0.64402,-1.57095,-20076506,-20787306,-26532084,4.533,0.0,0.0,-9.26067,USD,
1,Cedar Brook Corporate Center,4-B Cedar Brook Drive,Cranbury,NJ,08512,United States,609 495 2200,609 495 2202,https://palatin.com,Biotechnology,Healthcare,"Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL3994, a peptide mimetic molecule with amino acid mimetic structure and amino acids properties; and L8177, an oral peptide formulation for treatment of ulcerative colitis, which entered Phase 2 clinical trials. The company was founded in 1986 and is based in Cranbury, New Jersey.",33,"{'maxAge': 1, 'name': 'Mr. Stephen T. Wills CPA, CPA, MST', 'age': 65, 'title': 'CFO, COO, Exec. VP, Treasurer & Sec.', 'yearBorn': 1957, 'fiscalYear': 2022, 'totalPay': 870574, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,2.06,2.05,1.8,2.1094,2.06,2.05,1.8,2.1094,0.0,0.951244,-1.011236,242397,242397,83062,88300,88300,1.75,1.95,900,4000,20742300,1.8,8.6,5.3701982,2.2054,2.71785,0.0,0.0,USD,1909782,0.0,10521404,11523500,374540,401086,1690761600,1693440000,0.0325,0.06579,0.19712,3.25,0.033,0.86,2.093023,1656547200,1688083200,1680220800,-29595042,-2.55,-1.78,1:10,1285545600,0.494,-0.054,ASE,EQUITY,PTN,PTN,"Palatin Technologies, Inc.","Palatin Technologies, Inc.",876922200,America/New_York,EDT,-14400000,1.8,70.0,9.0,43.0,50.0,1.3,strong_buy,3,19632330,1.704,-35519496,799798,1.8,2.045,3862483,8.338,0.373,-0.64402,-1.57095,-20076506,-20787306,-26532084,4.533,0.0,0.0,-9.26067,USD,
2,Cedar Brook Corporate Center,4-B Cedar Brook Drive,Cranbury,NJ,08512,United States,609 495 2200,609 495 2202,https://palatin.com,Biotechnology,Healthcare,"Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL3994, a peptide mimetic molecule with amino acid mimetic structure and amino acids properties; and L8177, an oral peptide formulation for treatment of ulcerative colitis, which entered Phase 2 clinical trials. The company was founded in 1986 and is based in Cranbury, New Jersey.",33,"{'maxAge': 1, 'name': 'Burns  McClellan', 'title': 'VP of Investor Relations', 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,2.06,2.05,1.8,2.1094,2.06,2.05,1.8,2.1094,0.0,0.951244,-1.011236,242397,242397,83062,88300,88300,1.75,1.95,900,4000,20742300,1.8,8.6,5.3701982,2.2054,2.71785,0.0,0.0,USD,1909782,0.0,10521404,11523500,374540,401086,1690761600,1693440000,0.0325,0.06579,0.19712,3.25,0.033,0.86,2.093023,1656547200,1688083200,1680220800,-29595042,-2.55,-1.78,1:10,1285545600,0.494,-0.054,ASE,EQUITY,PTN,PTN,"Palatin Technologies, Inc.","Palatin Technologies, Inc.",876922200,America/New_York,EDT,-14400000,1.8,70.0,9.0,43.0,50.0,1.3,strong_buy,3,19632330,1.704,-35519496,799798,1.8,2.045,3862483,8.338,0.373,-0.64402,-1.57095,-20076506,-20787306,-26532084,4.533,0.0,0.0,-9.26067,USD,
3,Cedar Brook Corporate Center,4-B Cedar Brook Drive,Cranbury,NJ,08512,United States,609 495 2200,609 495 2202,https://palatin.com,Biotechnology,Healthcare,"Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL3994, a peptide mimetic molecule with amino acid mimetic structure and amino acids properties; and L8177, an oral peptide formulation for treatment of ulcerative colitis, which entered Phase 2 clinical trials. The company was founded in 1986 and is based in Cranbury, New Jersey.",33,"{'maxAge': 1, 'name': 'Mr. Stephen A. Slusher Esq.', 'title': 'Chief Legal Officer', 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,2.06,2.05,1.8,2.1094,2.06,2.05,1.8,2.1094,0.0,0.951244,-1.011236,242397,242397,83062,88300,88300,1.75,1.95,900,4000,20742300,1.8,8.6,5.3701982,2.2054,2.71785,0.0,0.0,USD,1909782,0.0,10521404,11523500,374540,401086,1690761600,1693440000,0.0325,0.06579,0.19712,3.25,0.033,0.86,2.093023,1656547200,1688083200,1680220800,-29595042,-2.55,-1.78,1:10,1285545600,0.494,-0.054,ASE,EQUITY,PTN,PTN,"Palatin Technologies, Inc.","Palatin Technologies, Inc.",876922200,America/New_York,EDT,-14400000,1.8,70.0,9.0,43.0,50.0,1.3,strong_buy,3,19632330,1.704,-35519496,799798,1.8,2.045,3862483,8.338,0.373,-0.64402,-1.57095,-20076506,-20787306,-26532084,4.533,0.0,0.0,-9.26067,USD,
4,Cedar Brook Corporate Center,4-B Cedar Brook Drive,Cranbury,NJ,08512,United States,609 495 2200,609 495 2202,https://palatin.com,Biotechnology,Healthcare,"Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL3994, a peptide mimetic molecule with amino acid mimetic structure and amino acids properties; and L8177, an oral peptide formulation for treatment of ulcerative colitis, which entered Phase 2 clinical trials. The company was founded in 1986 and is based in Cranbury, New Jersey.",33,"{'maxAge': 1, 'name': 'Dr. Michael B. Raizman M.D.', 'title': 'Chief Medical Officer', 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,2.06,2.05,1.8,2.1094,2.06,2.05,1.8,2.1094,0.0,0.951244,-1.011236,242397,242397,83062,88300,88300,1.75,1.95,900,4000,20742300,1.8,8.6,5.3701982,2.2054,2.71785,0.0,0.0,USD,1909782,0.0,10521404,11523500,374540,401086,1690761600,1693440000,0.0325,0.06579,0.19712,3.25,0.033,0.86,2.093023,1656547200,1688083200,1680220800,-29595042,-2.55,-1.78,1:10,1285545600,0.494,-0.054,ASE,EQUITY,PTN,PTN,"Palatin Technologies, Inc.","Palatin Technologies, Inc.",876922200,America/New_York,EDT,-14400000,1.8,70.0,9.0,43.0,50.0,1.3,strong_buy,3,19632330,1.704,-35519496,799798,1.8,2.045,3862483,8.338,0.373,-0.64402,-1.57095,-20076506,-20787306,-26532084,4.533,0.0,0.0,-9.26067,USD,
5,Cedar Brook Corporate Center,4-B Cedar Brook Drive,Cranbury,NJ,08512,United States,609 495 2200,609 495 2202,https://palatin.com,Biotechnology,Healthcare,"Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL3994, a peptide mimetic molecule with amino acid mimetic structure and amino acids properties; and L8177, an oral peptide formulation for treatment of ulcerative colitis, which entered Phase 2 clinical trials. The company was founded in 1986 and is based in Cranbury, New Jersey.",33,"{'maxAge': 1, 'name': 'Mr. James E. Hattersley', 'age': 62, 'title': 'Sr. VP of Bus. Devel.', 'yearBorn': 1960, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,2.06,2.05,1.8,2.1094,2.06,2.05,1.8,2.1094,0.0,0.951244,-1.011236,242397,242397,83062,88300,88300,1.75,1.95,900,4000,20742300,1.8,8.6,5.3701982,2.2054,2.71785,0.0,0.0,USD,1909782,0.0,10521404,11523500,374540,401086,1690761600,1693440000,0.0325,0.06579,0.19712,3.25,0.033,0.86,2.093023,1656547200,1688083200,1680220800,-29595042,-2.55,-1.78,1:10,1285545600,0.494,-0.054,ASE,EQUITY,PTN,PTN,"Palatin Technologies, Inc.","Palatin Technologies, Inc.",876922200,America/New_York,EDT,-14400000,1.8,70.0,9.0,43.0,50.0,1.3,strong_buy,3,19632330,1.704,-35519496,799798,1.8,2.045,3862483,8.338,0.373,-0.64402,-1.57095,-20076506,-20787306,-26532084,4.533,0.0,0.0,-9.26067,USD,
6,Cedar Brook Corporate Center,4-B Cedar Brook Drive,Cranbury,NJ,08512,United States,609 495 2200,609 495 2202,https://palatin.com,Biotechnology,Healthcare,"Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL3994, a peptide mimetic molecule with amino acid mimetic structure and amino acids properties; and L8177, an oral peptide formulation for treatment of ulcerative colitis, which entered Phase 2 clinical trials. The company was founded in 1986 and is based in Cranbury, New Jersey.",33,"{'maxAge': 1, 'name': 'Mr. John  Dodd Ph.D.', 'title': 'Sr. VP of Preclinical Devel.', 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,2.06,2.05,1.8,2.1094,2.06,2.05,1.8,2.1094,0.0,0.951244,-1.011236,242397,242397,83062,88300,88300,1.75,1.95,900,4000,20742300,1.8,8.6,5.3701982,2.2054,2.71785,0.0,0.0,USD,1909782,0.0,10521404,11523500,374540,401086,1690761600,1693440000,0.0325,0.06579,0.19712,3.25,0.033,0.86,2.093023,1656547200,1688083200,1680220800,-29595042,-2.55,-1.78,1:10,1285545600,0.494,-0.054,ASE,EQUITY,PTN,PTN,"Palatin Technologies, Inc.","Palatin Technologies, Inc.",876922200,America/New_York,EDT,-14400000,1.8,70.0,9.0,43.0,50.0,1.3,strong_buy,3,19632330,1.704,-35519496,799798,1.8,2.045,3862483,8.338,0.373,-0.64402,-1.57095,-20076506,-20787306,-26532084,4.533,0.0,0.0,-9.26067,USD,
7,Cedar Brook Corporate Center,4-B Cedar Brook Drive,Cranbury,NJ,08512,United States,609 495 2200,609 495 2202,https://palatin.com,Biotechnology,Healthcare,"Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL3994, a peptide mimetic molecule with amino acid mimetic structure and amino acids properties; and L8177, an oral peptide formulation for treatment of ulcerative colitis, which entered Phase 2 clinical trials. The company was founded in 1986 and is based in Cranbury, New Jersey.",33,"{'maxAge': 1, 'name': 'Mr. Robert  Jordan', 'title': 'Sr. VP of Program Operations', 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,2.06,2.05,1.8,2.1094,2.06,2.05,1.8,2.1094,0.0,0.951244,-1.011236,242397,242397,83062,88300,88300,1.75,1.95,900,4000,20742300,1.8,8.6,5.3701982,2.2054,2.71785,0.0,0.0,USD,1909782,0.0,10521404,11523500,374540,401086,1690761600,1693440000,0.0325,0.06579,0.19712,3.25,0.033,0.86,2.093023,1656547200,1688083200,1680220800,-29595042,-2.55,-1.78,1:10,1285545600,0.494,-0.054,ASE,EQUITY,PTN,PTN,"Palatin Technologies, Inc.","Palatin Technologies, Inc.",876922200,America/New_York,EDT,-14400000,1.8,70.0,9.0,43.0,50.0,1.3,strong_buy,3,19632330,1.704,-35519496,799798,1.8,2.045,3862483,8.338,0.373,-0.64402,-1.57095,-20076506,-20787306,-26532084,4.533,0.0,0.0,-9.26067,USD,
